Boostrix-Polio 2.5 Lf (Diphtheria Toxoid Adsorbed SUSPENSION) 2.5 LF

BOOSTRIX-POLIO 2.5 LF is a vaccine suspension designed to protect against diphtheria, tetanus, pertussis, and polio. This intramuscular injection is manufactured by GlaxoSmithKline Inc. and is suitable for specific age groups.

Strength

2.5 LF

Pack Size

0.5ML/10X0.5ML

Manufacturer / TM Owner

GLAXOSMITHKLINE INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

BOOSTRIX-POLIO 2.5 LF is used to prevent diphtheria, tetanus, pertussis, and polio. This vaccine is typically administered to individuals who have completed a primary series of diphtheria, tetanus, and pertussis vaccinations. It is often used as a booster shot to maintain immunity against these diseases.

Side Effects

Common effects of BOOSTRIX-POLIO 2.5 LF may include mild soreness, redness, or swelling at the injection site. Some individuals may experience mild fever, headache, or fatigue. These effects are usually temporary and resolve on their own.

Precautions & Warnings

BOOSTRIX-POLIO 2.5 LF should be stored as per the manufacturer's instructions to maintain its efficacy. It is important to inform healthcare providers about any allergies or medical conditions before administration. Follow the recommended schedule for vaccination.

Avoid Interactions

BOOSTRIX-POLIO 2.5 LF may interact with other medications or vaccines. It is advisable to consult a healthcare provider before taking this vaccine if you are on other medications. Avoid alcohol and other immune-suppressing substances unless advised otherwise.

Frequently Asked Questions

BOOSTRIX-POLIO 2.5 LF is used to prevent diphtheria, tetanus, pertussis, and polio. It is typically administered as a booster shot.

BOOSTRIX-POLIO 2.5 LF is administered intramuscularly, usually in the upper arm or thigh.

Common side effects may include mild soreness, redness, or swelling at the injection site, as well as mild fever, headache, or fatigue.

It is advisable to consult a healthcare provider before taking BOOSTRIX-POLIO 2.5 LF with other medications to avoid potential interactions.

Individuals with severe allergies to any component of the vaccine or those with a history of severe reactions to previous doses should avoid BOOSTRIX-POLIO 2.5 LF.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.